意大利儿童过敏与免疫学会关于儿童青少年重症哮喘管理的Delphi共识
该共识由意大利儿童过敏与免疫学会发起,采用改良Delphi流程,50名儿童哮喘专家对27条涉及流行病学、生物标志物、生物治疗及疗效评估的陈述进行迭代投票,共识定义为≥80%同意。所有27条陈述均达成共识(同意率82-100%,均分4.1-4.9),强调基于内型的生物治疗选择和多维疗效评估。
要点
- 重症哮喘约占儿童哮喘人群3-5%,生物治疗选择应基于内型。
- 所有27条陈述均达成共识,同意率82-100%,均分4.1-4.9。
- 推荐使用COMSA进行监测并分类应答者/超应答者/无应答者。
核心结论
- 该Delphi共识为儿童重症哮喘管理提供专家认可、循证的建议,强调基于生物标志物的个体化生物治疗选择和标准化结局指标的系统性应答监测。
研究设计与样本
- 采用改良Delphi流程,纳入50名儿童哮喘专家,经迭代轮次形成27条陈述,共识定义为5点Likert量表评分4-5分且≥80%同意。
主要发现
- 所有27条陈述均达成共识,同意范围82-100%,平均分4.1-4.9。
- 关键问题达成完全共识,包括基于内型选择治疗、2型炎症在儿童重症哮喘中占优势、现有生物制剂(奥马珠单抗、美泊利单抗、度普利尤单抗、特泽鲁单抗)的作用、多维应答评估(临床、功能、生物学)以及患者和家庭参与的重要性。
- 强共识支持使用重症哮喘核心结局指标(COMSA)进行监测、对应答者/超应答者/无应答者进行分类,以及选定生物标志物(包括血嗜酸性粒细胞计数≥300 cells/µL、FeNO和基线口服糖皮质激素剂量)的预测价值。
关键数值与推荐
- 共识定义为≥80%同意(5点Likert量表评分4-5分)。
- 血嗜酸性粒细胞计数≥300 cells/µL、FeNO和基线口服糖皮质激素剂量被支持作为预测性生物标志物。
- 推荐使用COMSA进行监测,并将应答分为应答者/超应答者/无应答者。
临床怎么用
- 临床中应基于内型(如2型炎症)和生物标志物(血嗜酸性粒细胞≥300 cells/µL、FeNO、基线OCS剂量)个体化选择生物制剂。
- 采用COMSA等标准化结局指标系统监测治疗应答,并按应答者/超应答者/无应答者进行分类管理。
- 重视患者和家庭参与重症哮喘的管理决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multidiscip Respir Med. 2026 Jul 20;21(1):1095. doi: 10.5826/mrm.2026.1095. ABSTRACT BACKGROUND: Severe asthma affects approximately 3-5% of the pediatric asthmatic population and is associated with substantial clinical, economic, and psychosocial burdens. Despite major advances in biological therapies, standardized guidance for their optimal use in children and adolescents remains limited. OBJECTIVE: To establish experts' consensus on the management of severe pediatric asthma through a Delphi process promoted by the Italian Society of Pediatric Allergy and Immunology (SIAIP), with particular focus on biological therapy selection, monitoring, and response assessment. METHODS: A modified Delphi process involving 50 pediatric asthma experts was conducted. Twenty-seven statements addressing epidemiology, pathophysiology, biomarkers, biological therapies, monitoring strategies, and response definitions were developed through iterative rounds. Consensus was defined as ≥80% agreement (scores 4-5 on a 5-point Likert scale). RESULTS: All 27 statements achieved consensus (agreement range: 82-100%; mean scores: 4.1-4.9). Complete consensus was reached on key issues, including the need for endotype-based therapy selection, the predominance of type 2 inflammation in severe pediatric asthma, the role of currently available biological therapies (omalizumab, mepolizumab, dupilumab, tezepelumab), multidimensional response assessment (clinical, functional, and biological), and the importance of patient and family engagement. Strong consensus also supported the use of Core Outcome Measures for Severe Asthma (COMSA) for monitoring, classification of responders/super-responders /non-responders, and the predictive value of selected biomarkers, including blood eosinophil counts (≥300 cells/µL), FeNO, and baseline oral corticosteroid dose. CONCLUSIONS: This Delphi Consensus provides expert-endorsed, evidence-based recommendations for the management of severe pediatric asthma, emphasizing personalized selection of biological therapy guided by biomarkers and systematic response monitoring using standardized outcome measures. PMID: 42474351 | PMC: PMC13557424 | DOI: 10.5826/mrm.2026.1095
引用
- 指南共识 · 哮喘:Delphi Consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP) on the management of severe asthma in children and adolescents
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。